Durham, North Carolina 27710

  • Metastatic Cancer


RATIONALE: Immunotherapy using CEA-treated white blood cells may help a person's body build an immune response to kill their tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of immunotherapy with CEA-treated white blood cells in treating patients with resected liver metastases from colon cancer.

Study summary:

OBJECTIVES: - Determine the cellular immune response to carcinoembryonic antigen pulsed dendritic cells in patients with adenocarcinoma of the colon metastatic to the liver. - Evaluate the overall and recurrence free survival in this patient population. OUTLINE: Patients undergo leukapheresis for up to 4.5 hours to collect dendritic cells. The separated dendritic cells are pulsed with carcinoembryonic antigen (CEA) RNA. Patients receive CEA RNA pulsed dendritic cells intravenously every 2 weeks for a total of 4 doses. Patients undergo a second leukapheresis 2 weeks after the last dendritic cell infusion to obtain specimens for immunologic tests. Patients with extra doses of dendritic cells available may receive additional doses of CEA RNA pulsed dendritic cells every 2 months in the absence of unacceptable toxicity. Patients are followed at weeks 12, 24, 36, and 48, and every 6 months thereafter. PROJECTED ACCRUAL: A total of 22 patients will be accrued for this study over 2 years.


DISEASE CHARACTERISTICS: - Histologically confirmed adenocarcinoma of the colon metastatic to the liver that expresses carcinoembryonic antigen (CEA) after resection with curative intent - At least 50% of the tumor cells must stain positive for CEA with at least moderate intensity - No gross residual disease after surgery PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Karnofsky 70-100% Life expectancy: - Greater than 6 months Hematopoietic: - Absolute neutrophil count at least 1000/mm 3 - Hemoglobin at least 9 g/dL - Platelet count at least 100,000/mm^3 Hepatic: - Bilirubin less than 2.0 mg/dL - No chronic or acute hepatic disease Renal: - Creatinine less than 2.5 mg/dL Cardiovascular: - No chronic or acute cardiac disease (New York Heart Association class III or IV) Pulmonary: - No chronic or acute pulmonary illness such as asthma or chronic obstructive pulmonary disease Other: - Not pregnant or nursing - No other prior or concurrent malignancy except nonmelanoma skin cancer or controlled superficial bladder cancer within the past 5 years - No history of autoimmune disease such as inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, and multiple sclerosis - No active acute or chronic infection such as urinary tract infection, HIV, or viral hepatitis - No active infectious enteritis or eosinophilic enteritis PRIOR CONCURRENT THERAPY: Biologic therapy: - No other concurrent immunotherapy Chemotherapy: - No concurrent chemotherapy - At least 6 weeks since prior chemotherapy Endocrine therapy: - No concurrent steroid therapy (or any other immunosuppressives) - At least 6 weeks since prior steroid therapy Radiotherapy: - No concurrent radiotherapy - At least 6 weeks since prior radiotherapy Surgery: - Recovered from prior surgery



Primary Contact:

Study Chair
Herbert K. Lyerly, MD
Duke Cancer Institute

Backup Contact:


Location Contact:

Durham, North Carolina 27710
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: April 07, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.